KCT0000409已完成未知
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of S-297995 for the Treatment of Opioid-induced Constipation (OIC) in Cancer Patients
Shionogi0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 18(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •Cancer patients with constipation associated with administration of opioid analgesics who meet the following criteria:
- •Patients whose SBM (spontaneous bowel movement) frequency during the 14 days prior to enrollment is 5 times or less, and who experience at least one of the following symptoms of bowel movements
- •- Straining during bowel movement
- •- Feeling of incomplete evacuation
- •- Passage of hard stools or pellets etc.
排除标准
- •Patients with constipation potentially attributable to causes other than opioid analgesics
- •Patients with clinically significant gastrointestinal disorders
- •Patients with hepatic or renal disorders, etc
研究者
相似试验
进行中（未招募）
1 期
A Phase 2b study for adults hospitalized with Respiratory Syncytial Virus.Respiratory Syncytial Virus InfectionEUCTR2016-001653-40-ESJanssen-Cilag International NV90
进行中（未招募）
1 期
A controlled clinical trial to study RM-131 (relamorelin) in patients with vomiting symptoms and diabetic gastroparesisVomiting symptoms in patient with moderate to severe diabetic gastroparesisMedDRA version: 17.1Level: PTClassification code 10051153Term: Diabetic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2014-005623-27-SERhythm Pharmaceuticals, Inc.395
招募中
2 期
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC (EMERALD-2)CTRI/2023/05/052163Morphic Therapeutic, Inc.
进行中（未招募）
不适用
A study of the safety and drug effects of levodopa inhalation powder (CVT-301) in patients with Parkinson’s diseaseMedDRA version: 14.1Level: LLTClassification code 10034007Term: Parkinson's disease NOSSystem Organ Class: 100000004852Parkinson's DiseaseEUCTR2012-005822-31-GBCivitas Therapeutics, Inc.80
进行中（未招募）
1 期
A double-blind, placebo-controlled Clinical Trial to evaluate the Safety and Efficacy of JNJ-64304500 in patients with Moderately to Severely Active Crohn¿s DiseaseEUCTR2016-000634-21-ITJANSSEN CILAG INTERNATIONAL NV654